2,6-diaminopurine has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Amblard, F; Amiralaei, S; Bassit, L; Bobeck, D; Cho, JH; Coats, SJ; Detorio, M; Ehteshami, M; McBrayer, TR; Pradere, U; Schinazi, RF; Tao, S; Whitaker, T; Zhang, HW; Zhou, L | 1 |
1 other study(ies) available for 2,6-diaminopurine and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
Article | Year |
---|---|
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
Topics: 2-Aminopurine; Amides; Antiviral Agents; Cell Line; Cells, Cultured; Guanosine Triphosphate; Hepacivirus; Hepatitis C; Humans; Methylation; Phosphoric Acids; Prodrugs; Ribonucleosides | 2015 |